![Elvire Gouze](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Elvire Gouze
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Innoskel SASU
![]() Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Algemeen Directeur | - | - |
Oprichter | - | - |
Loopbaan van Elvire Gouze
Eerdere bekende functies van Elvire Gouze
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Therachon SAS
![]() Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Oprichter | 01-01-2014 | - |
Statistieken
Internationaal
Frankrijk | 3 |
Operationeel
Founder | 2 |
Chief Executive Officer | 1 |
Sectoraal
Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Therachon SAS
![]() Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Health Technology |
Innoskel SASU
![]() Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Health Technology |
- Beurs
- Insiders
- Elvire Gouze
- Ervaring